Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
- PMID: 11237840
- DOI: 10.1086/319284
Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
Abstract
Human immunodeficiency virus type 1 (HIV-1) entry proceeds via a cascade of events that afford promising targets for therapy. PRO 542 neutralizes HIV-1 by blocking its attachment to CD4 cells, and T-20 blocks gp41-mediated fusion. Both drugs have shown promise in phase 1/2 clinical trials. Here, the drugs were tested individually and in combination in preclinical models of HIV-1 infection, and inhibition data were analyzed for cooperativity by using the combination index method. Synergistic inhibition of virus-cell and cell-cell fusion was observed for phenotypically diverse viruses for a broad range of drug concentrations, often resulting in > or = 10-fold dose reductions in vitro. Additional mechanism-of-action studies probed the molecular basis of the synergies. The markedly enhanced activity observed for the PRO 542:T-20 combination indicates that the multistep nature of HIV-1 entry leaves the virus particularly vulnerable to combinations of entry inhibitors. These findings provide a strong rationale for evaluating combinations of these promising agents for therapy in vivo.
Similar articles
-
Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.AIDS Res Hum Retroviruses. 1993 Jul;9(7):581-7. doi: 10.1089/aid.1993.9.581. AIDS Res Hum Retroviruses. 1993. PMID: 8369162
-
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.Antivir Ther. 2003 Apr;8(2):155-61. Antivir Ther. 2003. PMID: 12741628
-
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.J Virol. 2003 Feb;77(4):2762-7. doi: 10.1128/jvi.77.4.2762-2767.2003. J Virol. 2003. PMID: 12552019 Free PMC article.
-
Resistance to HIV-1 entry inhibitors.Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94. doi: 10.2174/1568005033481015. Curr Drug Targets Infect Disord. 2003. PMID: 14754430 Review.
-
HIV entry inhibitors: a new generation of antiretroviral drugs.Acta Pharmacol Sin. 2005 Oct;26(10):1165-73. doi: 10.1111/j.1745-7254.2005.00193.x. Acta Pharmacol Sin. 2005. PMID: 16174430 Review.
Cited by
-
[HIV entry into the cells--mechanisms and therapeutic possibilities].Med Clin (Barc). 2006 Mar 11;126(9):341-8. doi: 10.1157/13085735. Med Clin (Barc). 2006. PMID: 16650368 Free PMC article. Review. Spanish.
-
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96. doi: 10.1128/AAC.00699-06. Antimicrob Agents Chemother. 2006. PMID: 17005807 Free PMC article.
-
CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity.PLoS Biol. 2019 Jan 16;17(1):e3000114. doi: 10.1371/journal.pbio.3000114. eCollection 2019 Jan. PLoS Biol. 2019. PMID: 30650070 Free PMC article.
-
A review of the toxicity of HIV medications.J Med Toxicol. 2014 Mar;10(1):26-39. doi: 10.1007/s13181-013-0325-8. J Med Toxicol. 2014. PMID: 23963694 Free PMC article. Review.
-
Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22. J Virol. 2011. PMID: 21697467 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
